Christian Lildal Carranza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Lildal Carranza has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Helena Dominguez
Bisperbjerg-Frederiksberg Hospital, 2400 Copenhagen, Denmark
4 shared publications Peter Skov Olsen
Department of Cardiothoracic Surgery; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark
4 shared publications- Andreas Kjaer
Rigshospitalet
3 shared publications Christian Gluud
Centre for Clinical Intervention Research, Copenhagen Trial Unit, The Capital Region, Copenhagen University Hospital − Rigshospitalet, Copenhagen, Denmark
3 shared publications- Christian Gluud
Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Department 7812, Copenhagen University Hospital ─ Rigshospitalet, Copenhagen, Denmark
3 shared publications - Janus Christian Jakobsen
Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, The Capital Region, Denmark
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
Multiple recurrence of Cardiac Myxoma in patient with Carney Complex: a case report
Background: Cardiac myxomas are rare but represent the most common primary cardiac tumour. Most are sporadic, solitary, and associated with a low risk of recurrence. Recurrent, multiple, or atypically located cardiac myxomas should raise suspicion of an underlying hereditary syndrome, particularly Carney complex. Case summary: a 24-year-old man presented with pulmonary embolism caused by a right atrial cardiac myxoma and underwent complete surgical resection. Fourteen years later, he presented with systemic peripheral arterial emboli due to a left atrial myxoma and again underwent surgery. At routine echocardiographic follow-up two years later, an asymptomatic recurrent atrial myxoma was detected and he underwent his third cardiac surgery. Genetic evaluation subsequently identified a likely pathogenetic PRKAR1A variant, molecularly confirming the diagnosis of Carney complex. Discussion: Recurrence after complete resection of sporadic myxoma is uncommon, and routine long-term echocardiographic surveillance is therefore not universally recommended. However, young age at presentation, recurrent or multiple tumours, atypical cardiac locations, or other features suggestive of Carney complex should prompt genetic evaluation and closer follow-up. Recognition of Carney complex has important implications for lifelong surveillance and multidisciplinary management.
- 10 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
Open AccessMultiple recurrence of Cardiac Myxoma in patient with Carney Complex: a case report
Background: Cardiac myxomas are rare but represent the most common primary cardiac tumour. Most are sporadic, solitary, and associated with a low risk of recurrence. Recurrent, multiple, or atypically located cardiac myxomas should raise suspicion of an underlying hereditary syndrome, particularly Carney complex. Case summary: a 24-year-old man presented with pulmonary embolism caused by a right atrial cardiac myxoma and underwent complete surgical resection. Fourteen years later, he presented with systemic peripheral arterial emboli due to a left atrial myxoma and again underwent surgery. At routine echocardiographic follow-up two years later, an asymptomatic recurrent atrial myxoma was detected and he underwent his third cardiac surgery. Genetic evaluation subsequently identified a likely pathogenetic PRKAR1A variant, molecularly confirming the diagnosis of Carney complex. Discussion: Recurrence after complete resection of sporadic myxoma is uncommon, and routine long-term echocardiographic surveillance is therefore not universally recommended. However, young age at presentation, recurrent or multiple tumours, atypical cardiac locations, or other features suggestive of Carney complex should prompt genetic evaluation and closer follow-up. Recognition of Carney complex has important implications for lifelong surveillance and multidisciplinary management.
- Open Access
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Changes in loop diuretic use following mitral valve surgery for mitral regurgitation according to age: a nationwide cohort study
Background: Loop diuretic use (LDU) may provide complementary information on post-operative heart failure (HF) burden after mitral valve surgery (MVS). Aims: We investigated changes in LDU before and after MVS for mitral regurgitation (MR) and assessed post-operative HF admission according to age. Methods and results: Using Danish nationwide registries, we identified patients aged ≥18 years discharged after first-time MVS for MR between 1996 and 2022. LDU was assessed from redeemed prescriptions before surgery and at post-operative landmarks. HF admission within 5 years was estimated with death as a competing risk. Among 6840 patients, LDU was 46.2% before surgery and declined among survivors to 27.0% at 12–15 months and 23.7% at 36–39 months. Pre-operative use was more frequent with increasing age, ranging from 27.9% in patients aged 18–49 years to 64.3% in those aged ≥80 years. Postoperatively, LDU remained common, ranging from 13.5% to 41.6% at 12–15 months and from 11.9% to 35.4% at 36–39 months across age groups. The 5-year cumulative incidence of HF admission was 20.9% (95% CI: 20.0–22.0%) overall and increased across age groups, from 13.9% to 27.4%. Pre-operative LDU was associated with higher 5-year mortality irrespective of recorded HF status. Conclusions: LDU declined after MVS for MR but remained common, particularly among older patients, and showed an age-related pattern consistent with hospital admission for HF.
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Open AccessChanges in loop diuretic use following mitral valve surgery for mitral regurgitation according to age: a nationwide cohort study
Background: Loop diuretic use (LDU) may provide complementary information on post-operative heart failure (HF) burden after mitral valve surgery (MVS). Aims: We investigated changes in LDU before and after MVS for mitral regurgitation (MR) and assessed post-operative HF admission according to age. Methods and results: Using Danish nationwide registries, we identified patients aged ≥18 years discharged after first-time MVS for MR between 1996 and 2022. LDU was assessed from redeemed prescriptions before surgery and at post-operative landmarks. HF admission within 5 years was estimated with death as a competing risk. Among 6840 patients, LDU was 46.2% before surgery and declined among survivors to 27.0% at 12–15 months and 23.7% at 36–39 months. Pre-operative use was more frequent with increasing age, ranging from 27.9% in patients aged 18–49 years to 64.3% in those aged ≥80 years. Postoperatively, LDU remained common, ranging from 13.5% to 41.6% at 12–15 months and from 11.9% to 35.4% at 36–39 months across age groups. The 5-year cumulative incidence of HF admission was 20.9% (95% CI: 20.0–22.0%) overall and increased across age groups, from 13.9% to 27.4%. Pre-operative LDU was associated with higher 5-year mortality irrespective of recorded HF status. Conclusions: LDU declined after MVS for MR but remained common, particularly among older patients, and showed an age-related pattern consistent with hospital admission for HF.
- Open Access
- 30 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3440
Convergent Hybrid Ablation and Concomitant Left Atrial Appendage Exclusion for Stroke Prevention and Rhythm Control in Persistent Atrial Fibrillation
Background/Objectives: Persistent and long-standing persistent atrial fibrillation (AF) presents a therapeutic clinical challenge balancing complex rhythm management with a heightened stroke risk. The left atrial appendage (LAA) is the primary source of thromboembolisms in these patients. This study evaluated the safety and efficacy of combining LAA exclusion with Convergent Hybrid Ablation for stroke prevention and rhythm control in a refractory patient cohort. Methods: A single-center observational cohort study was conducted including 28 patients with symptomatic persistent or long-standing persistent AF. The cohort was highly refractory, with 82.1% having failed at least one endocardial catheter ablation. The hybrid procedure consisted of sub-xiphoid epicardial ablation, thoracoscopic LAA exclusion (AtriClip), and endocardial catheter ablation. Safety and efficacy were assessed at 3 months and 12 months. Results: LAA exclusion was successfully performed in 96.4% of patients. The peri-operative safety profile was acceptable, with zero procedure-related strokes or deaths. At the 12-month follow-up, the rate of stroke or any other major adverse events was at 0.0%. Freedom from AF was 75.0%, shown by a 12-lead electrocardiography (ECG). Freedom from any atrial arrhythmia off anti-arrhythmic drugs (AADs) was achieved in 50.0% of patients. A total of 32.1% of the cohort required catheter ablation within 12 months to maintain sinus rhythm as part of the hybrid treatment. Conclusions: Concomitant LAA exclusion during Convergent Hybrid Ablation is a safe procedure with a high clinical success rate in maintaining sinus rhythm in a highly complex AF patient group. While no thromboembolic events were observed at 12 months, larger studies with longer follow-up are needed to confirm the potential for long-term stroke risk reduction. The findings suggest that for many patients, the hybrid procedure should be viewed as part of a multi-step strategy often requiring endocardial “touch-up” ablation.
- 30 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3440
Open AccessConvergent Hybrid Ablation and Concomitant Left Atrial Appendage Exclusion for Stroke Prevention and Rhythm Control in Persistent Atrial Fibrillation
Background/Objectives: Persistent and long-standing persistent atrial fibrillation (AF) presents a therapeutic clinical challenge balancing complex rhythm management with a heightened stroke risk. The left atrial appendage (LAA) is the primary source of thromboembolisms in these patients. This study evaluated the safety and efficacy of combining LAA exclusion with Convergent Hybrid Ablation for stroke prevention and rhythm control in a refractory patient cohort. Methods: A single-center observational cohort study was conducted including 28 patients with symptomatic persistent or long-standing persistent AF. The cohort was highly refractory, with 82.1% having failed at least one endocardial catheter ablation. The hybrid procedure consisted of sub-xiphoid epicardial ablation, thoracoscopic LAA exclusion (AtriClip), and endocardial catheter ablation. Safety and efficacy were assessed at 3 months and 12 months. Results: LAA exclusion was successfully performed in 96.4% of patients. The peri-operative safety profile was acceptable, with zero procedure-related strokes or deaths. At the 12-month follow-up, the rate of stroke or any other major adverse events was at 0.0%. Freedom from AF was 75.0%, shown by a 12-lead electrocardiography (ECG). Freedom from any atrial arrhythmia off anti-arrhythmic drugs (AADs) was achieved in 50.0% of patients. A total of 32.1% of the cohort required catheter ablation within 12 months to maintain sinus rhythm as part of the hybrid treatment. Conclusions: Concomitant LAA exclusion during Convergent Hybrid Ablation is a safe procedure with a high clinical success rate in maintaining sinus rhythm in a highly complex AF patient group. While no thromboembolic events were observed at 12 months, larger studies with longer follow-up are needed to confirm the potential for long-term stroke risk reduction. The findings suggest that for many patients, the hybrid procedure should be viewed as part of a multi-step strategy often requiring endocardial “touch-up” ablation.
- Open Access
- 27 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3338
Complications and Patient Satisfaction After Endoscopic Radial Artery Harvest: A Retrospective Cohort Study
Background/Objectives: This study aimed to assess complications after endoscopic radial artery harvest, evaluate patient satisfaction, and assess the feasibility of a questionnaire interview. The primary aim was to assess neurological damage after endoscopic radial artery harvest (ERAH), and the secondary aim was to assess the feasibility of a newly constructed questionnaire in Danish. Methods: From June 2010 through October 2012, 108 patients underwent endoscopic radial artery harvest for coronary artery bypass grafting (CABG) at our institution. A total of 100 patients were interviewed by phone between one and two years after the operation. The interviews included questions about infection, bleeding, neurological damage, vascular perfusion of the hand, re-intervention, and general satisfaction with the procedure. Results: The described cohort was mainly male (88.9% 95% confidence interval (CI) 90.5–98.4%) with a mean age of 60.8 years (standard deviation (SD) 9.0). The self-reported incidence of postoperative antibiotic treatment was 7.0% (95% CI 3.1–14.4%), sensory deficit 18.0% (95% CI 11.3–27.2%), pain 8.0% (95% CI 3.8–15.6%), motoric deficit 4.0% (95% CI 1.3–10.5%) and cold or pale fingers 9.0% (95% CI 4.5–16.8%). At a follow-up time with a mean of 1.40 years (range 0.97–2.37 years, SD 0.36), all incisions were healed satisfactorily, 12.0% (95% CI 6.6–20.4%) reported sensory deficit, 7.0% (95% CI 3.1–14.4%) reported pain, 2.0% (95% CI 0.3–7.7%) reported motoric deficit, and none had a tendency towards cold fingers. The mean duration of antibiotic treatment was 8.7 days ± 2.3. When asked to rate the endoscopic procedure points of satisfaction from 0 (worst) to 10 (best), the mean was 9.7 ± 0.7. Conclusions: This study reports the occurrence of surgical complications immediately after ERAH, with an occurrence of self-reported neurological deficits of 18%. A questionnaire was feasible in a cohort of postoperative patients receiving radial artery harvest.
- 27 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3338
Open AccessComplications and Patient Satisfaction After Endoscopic Radial Artery Harvest: A Retrospective Cohort Study
Background/Objectives: This study aimed to assess complications after endoscopic radial artery harvest, evaluate patient satisfaction, and assess the feasibility of a questionnaire interview. The primary aim was to assess neurological damage after endoscopic radial artery harvest (ERAH), and the secondary aim was to assess the feasibility of a newly constructed questionnaire in Danish. Methods: From June 2010 through October 2012, 108 patients underwent endoscopic radial artery harvest for coronary artery bypass grafting (CABG) at our institution. A total of 100 patients were interviewed by phone between one and two years after the operation. The interviews included questions about infection, bleeding, neurological damage, vascular perfusion of the hand, re-intervention, and general satisfaction with the procedure. Results: The described cohort was mainly male (88.9% 95% confidence interval (CI) 90.5–98.4%) with a mean age of 60.8 years (standard deviation (SD) 9.0). The self-reported incidence of postoperative antibiotic treatment was 7.0% (95% CI 3.1–14.4%), sensory deficit 18.0% (95% CI 11.3–27.2%), pain 8.0% (95% CI 3.8–15.6%), motoric deficit 4.0% (95% CI 1.3–10.5%) and cold or pale fingers 9.0% (95% CI 4.5–16.8%). At a follow-up time with a mean of 1.40 years (range 0.97–2.37 years, SD 0.36), all incisions were healed satisfactorily, 12.0% (95% CI 6.6–20.4%) reported sensory deficit, 7.0% (95% CI 3.1–14.4%) reported pain, 2.0% (95% CI 0.3–7.7%) reported motoric deficit, and none had a tendency towards cold fingers. The mean duration of antibiotic treatment was 8.7 days ± 2.3. When asked to rate the endoscopic procedure points of satisfaction from 0 (worst) to 10 (best), the mean was 9.7 ± 0.7. Conclusions: This study reports the occurrence of surgical complications immediately after ERAH, with an occurrence of self-reported neurological deficits of 18%. A questionnaire was feasible in a cohort of postoperative patients receiving radial artery harvest.
- Open Access
- 31 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6)
Associated mortality and time spent in hospital following mitral valve intervention for mitral regurgitation according to frailty status: a nationwide Danish study
Aims: Little is known about how patient frailty affects mortality and hospitalization following mitral valve intervention for mitral regurgitation (MR). Methods and results: Using Danish nationwide registries, we identified patients undergoing first-time mitral valve intervention for MR during the period 1996–2022. Patients were categorized as frail or non-frail based on the Hospital Frailty Risk Score. We assessed 1 year mortality with the reverse Kaplan–Meier estimator, and adjusted comparisons were computed using multivariable-adjusted Cox regression analysis. A composite outcome of death or time in hospital >14 days within 1 year was examined using multivariable-adjusted logistic regression analysis. A total of 7000 patients (90.0%) were considered non-frail (median age 67.0 years, 66.3% male) and 782 (10.0%) were considered frail (median age 71.0 years, 56.3% male). One year mortality was 8.2% among non-frail patients and 13.4% among frail patients (P-value 28 days. Among frail patients, the corresponding proportions were 26.6%, 46.3%, 9.1%, and 9.8%. In the adjusted analysis, frail patients were associated with higher odds of the composite outcome [odds ratio = 1.65 (95% CI: 1.37–2.00)]. Conclusion: Frail patients were associated with more time spent in hospital within the first year following surgery compared with non-frail patients, but no statistically significant difference was found in the 1 year mortality according to frailty status in adjusted analysis.
- 31 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6)
Open AccessAssociated mortality and time spent in hospital following mitral valve intervention for mitral regurgitation according to frailty status: a nationwide Danish study
Aims: Little is known about how patient frailty affects mortality and hospitalization following mitral valve intervention for mitral regurgitation (MR). Methods and results: Using Danish nationwide registries, we identified patients undergoing first-time mitral valve intervention for MR during the period 1996–2022. Patients were categorized as frail or non-frail based on the Hospital Frailty Risk Score. We assessed 1 year mortality with the reverse Kaplan–Meier estimator, and adjusted comparisons were computed using multivariable-adjusted Cox regression analysis. A composite outcome of death or time in hospital >14 days within 1 year was examined using multivariable-adjusted logistic regression analysis. A total of 7000 patients (90.0%) were considered non-frail (median age 67.0 years, 66.3% male) and 782 (10.0%) were considered frail (median age 71.0 years, 56.3% male). One year mortality was 8.2% among non-frail patients and 13.4% among frail patients (P-value 28 days. Among frail patients, the corresponding proportions were 26.6%, 46.3%, 9.1%, and 9.8%. In the adjusted analysis, frail patients were associated with higher odds of the composite outcome [odds ratio = 1.65 (95% CI: 1.37–2.00)]. Conclusion: Frail patients were associated with more time spent in hospital within the first year following surgery compared with non-frail patients, but no statistically significant difference was found in the 1 year mortality according to frailty status in adjusted analysis.
- Open Access
- 23 June 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 438, 133552
Trends in mitral valve surgery for mitral valve regurgitation in Denmark: Changes in patient characteristics and mortality from 1996 to 2022
- 23 June 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 438, 133552
Open AccessTrends in mitral valve surgery for mitral valve regurgitation in Denmark: Changes in patient characteristics and mortality from 1996 to 2022
- Open Access
Implementation of Minimally Invasive Mitral Valve Surgery in a Novice Center
Background/Objectives: The complexity of Minimally Invasive Mitral Valve Surgery (MIMVS) could cause a slow learning curve and potentially patient harm. We thus investigated if a novice mitral valve center encountered difficulties implementing MIMVS. Methods: We investigated seven hundred and forty-eight mitral valve surgery patients, two years before and after MIMVS introduction. Results: We propensity score matched two hundred and sixty elective mitral valve patients for comparison, with one hundred and thirty patients in each group. Surgical- (5.5 vs. 4.3 h), Cardiopulmonary bypass- (180 vs. 102 min) and aortic cross-clamp times (98 vs. 81 min) became longer after MIMVS introduction. One-year mortality and in-hospital outcomes remained unaffected. Hospital length of stay shortened significantly after MIMVS (5 d vs. 7 d; p < 0.001). Conclusions: Adopting MIMVS in a mitral valve center without prior experience in the procedure showed feasibility, equally good outcome and shorter hospital stay when compared to conventional sternotomy.
Open AccessImplementation of Minimally Invasive Mitral Valve Surgery in a Novice Center
Background/Objectives: The complexity of Minimally Invasive Mitral Valve Surgery (MIMVS) could cause a slow learning curve and potentially patient harm. We thus investigated if a novice mitral valve center encountered difficulties implementing MIMVS. Methods: We investigated seven hundred and forty-eight mitral valve surgery patients, two years before and after MIMVS introduction. Results: We propensity score matched two hundred and sixty elective mitral valve patients for comparison, with one hundred and thirty patients in each group. Surgical- (5.5 vs. 4.3 h), Cardiopulmonary bypass- (180 vs. 102 min) and aortic cross-clamp times (98 vs. 81 min) became longer after MIMVS introduction. One-year mortality and in-hospital outcomes remained unaffected. Hospital length of stay shortened significantly after MIMVS (5 d vs. 7 d; p < 0.001). Conclusions: Adopting MIMVS in a mitral valve center without prior experience in the procedure showed feasibility, equally good outcome and shorter hospital stay when compared to conventional sternotomy.
- Open Access
- 5 March 2025
- Published by MDPI AG in Preprints.org
Implementation of Minimally Invasive Mitral Valve Surgery in a Novice Center
Background/Objectives: To investigate if mitral valve centers encounter challenges implementing Minimally Invasive Mitral Valve Surgery (MIMVS). Methods: We investigated mitral valve surgery patients, before and after MIMVS introduction. Results: We propensity score matched two hundred and sixty elective mitral valve patients for comparison. Surgical- (5.5 vs 4.3h), CPB- (180 vs 102 min) and aortic cross-clamp times (98 vs. 81 min) became longer after MIMVS introduction. One year mortality and in-hospital outcomes remained unaffected. Hospital length of stay shortened significantly after MIMVS (5d vs 7d p<0.001). Conclusion: Adopting MIMVS in a mitral valve center without prior experience in the procedure showed feasibility, equally good outcome and shorter hospital stay when compared to conventional sternotomy.
- 5 March 2025
- Published by MDPI AG in Preprints.org
Open AccessImplementation of Minimally Invasive Mitral Valve Surgery in a Novice Center
Background/Objectives: To investigate if mitral valve centers encounter challenges implementing Minimally Invasive Mitral Valve Surgery (MIMVS). Methods: We investigated mitral valve surgery patients, before and after MIMVS introduction. Results: We propensity score matched two hundred and sixty elective mitral valve patients for comparison. Surgical- (5.5 vs 4.3h), CPB- (180 vs 102 min) and aortic cross-clamp times (98 vs. 81 min) became longer after MIMVS introduction. One year mortality and in-hospital outcomes remained unaffected. Hospital length of stay shortened significantly after MIMVS (5d vs 7d p<0.001). Conclusion: Adopting MIMVS in a mitral valve center without prior experience in the procedure showed feasibility, equally good outcome and shorter hospital stay when compared to conventional sternotomy.
- 10 June 2023
- Published by Elsevier in American Heart Journal
- Vol. 264, 133-142
The left atrial appendage closure by surgery-2 (LAACS-2) trial protocol rationale and design of a randomized multicenter trial investigating if left atrial appendage closure prevents stroke in patients undergoing open-heart surgery irrespective of preoperative atrial fibrillation status and stroke risk
- 10 June 2023
- Published by Elsevier in American Heart Journal
- Vol. 264, 133-142
The left atrial appendage closure by surgery-2 (LAACS-2) trial protocol rationale and design of a randomized multicenter trial investigating if left atrial appendage closure prevents stroke in patients undergoing open-heart surgery irrespective of preoperative atrial fibrillation status and stroke risk
- Open Access
- 9 December 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-13
Detailed statistical analysis plan for the neurological complications in endoscopic versus open radial artery harvest (NEO) randomised clinical trial
Introduction: Coronary artery bypass grafting can be conducted using the radial artery as a bypass graft. However, it remains unclear which harvesting method is superior, i.e. endoscopic or open radial artery, and which site for proximal anastomosis of the radial artery has the greatest benefits? Methods: The NEO Trial is a single site randomised clinical trial with a 2 × 2 factorial design. The first comparison assesses endoscopic versus open radial artery harvest with a primary outcome of hand function and secondary outcomes of neurological deficits through clinical exams and neurophysiological studies. The primary outcome is postoperatively hand function at three months. We anticipate a mean difference of 3 points with a standard deviation of 8 points, a power of 90%, and a type I error of 5%, resulting in a required sample size of 300 participants randomised 1:1. Secondary outcomes are neurological deficits (based on nerve conduction measurements, algometry test and von Frey hair test), clinical neurological examination of cutaneous sensibility, and registration of complications in the donor arm (haematoma formation, wound dehiscence, and/or infection). The second comparison assesses two different proximal anastomotic sites, i.e. aorto-radial anastomosis versus mammario-radial anastomosis. The primary outcome is a composite of cerebrovascular events and the secondary outcome is graft patency evaluation by multi-slice computer tomography-scan. These outcomes will be assessed at 1 year postoperatively, and the results of this comparison will be exploratory only. Both comparisons will be analysed using intention-to-treat and intervention groups will be compared using linear regression, logistic regression, or Mann–Whitney U test depending on data type. Two independent statisticians will follow the present plan and conduct the analyses which will hereafter be fused into a final analysis based on consensus. Conclusion: This detailed analysis plan will increase the validity of the NEO trial results by predefining the statistical analysis in detail. Trial registration: ClinicalTrials.gov identifier: NCT01848886. Registered 25 February 2013. Danish Ethics committee number: H-3–2012-116. Danish Data Protection Agency: 2007–58-0015/jr. n:30–0838.
- 9 December 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-13
Open AccessDetailed statistical analysis plan for the neurological complications in endoscopic versus open radial artery harvest (NEO) randomised clinical trial
Introduction: Coronary artery bypass grafting can be conducted using the radial artery as a bypass graft. However, it remains unclear which harvesting method is superior, i.e. endoscopic or open radial artery, and which site for proximal anastomosis of the radial artery has the greatest benefits? Methods: The NEO Trial is a single site randomised clinical trial with a 2 × 2 factorial design. The first comparison assesses endoscopic versus open radial artery harvest with a primary outcome of hand function and secondary outcomes of neurological deficits through clinical exams and neurophysiological studies. The primary outcome is postoperatively hand function at three months. We anticipate a mean difference of 3 points with a standard deviation of 8 points, a power of 90%, and a type I error of 5%, resulting in a required sample size of 300 participants randomised 1:1. Secondary outcomes are neurological deficits (based on nerve conduction measurements, algometry test and von Frey hair test), clinical neurological examination of cutaneous sensibility, and registration of complications in the donor arm (haematoma formation, wound dehiscence, and/or infection). The second comparison assesses two different proximal anastomotic sites, i.e. aorto-radial anastomosis versus mammario-radial anastomosis. The primary outcome is a composite of cerebrovascular events and the secondary outcome is graft patency evaluation by multi-slice computer tomography-scan. These outcomes will be assessed at 1 year postoperatively, and the results of this comparison will be exploratory only. Both comparisons will be analysed using intention-to-treat and intervention groups will be compared using linear regression, logistic regression, or Mann–Whitney U test depending on data type. Two independent statisticians will follow the present plan and conduct the analyses which will hereafter be fused into a final analysis based on consensus. Conclusion: This detailed analysis plan will increase the validity of the NEO trial results by predefining the statistical analysis in detail. Trial registration: ClinicalTrials.gov identifier: NCT01848886. Registered 25 February 2013. Danish Ethics committee number: H-3–2012-116. Danish Data Protection Agency: 2007–58-0015/jr. n:30–0838.